Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,354.40 +121.18 0.80%
S&P 500 1,667.47 +17.00 1.03%
Nasdaq 3,498.97 +33.72 0.97%
Ticker Volume Price Price Delta
STOXX 50 2,817.99 +11.29 0.40%
FTSE 100 6,723.06 +35.26 0.53%
DAX 8,398.00 +28.13 0.34%
Ticker Volume Price Price Delta
Nikkei 15,138.10 +100.88 0.67%
Hang Seng 23,082.70 +38.44 0.17%
S&P/ASX 200 5,180.77 +15.11 0.29%
  • Fund Type: SICAV
  • Objective: Sector Fund-Health & Biotech
  • Asset Class: Equity
  • Geographic Focus: Global

Dexia Equities B - Pharma Plus

+ Add to Watchlist

CRE2489:BB

1,797.44 USD 10.07 0.56%

As of 00:59:30 ET on 05/16/2013.

Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Snapshot for Dexia Equities B - Pharma Plus (CRE2489)

Year To Date: +20.99% 3-Month: +11.58% 3-Year: +16.12% 52-Week Range: 1,315.37 - 1,807.51
1-Month: +2.03% 1-Year: +33.89% 5-Year: +8.41% Beta vs MXWO0HC: 1.00

Mutual Fund Chart for CRE2489

No chart data available.
  • CRE2489:BB 1,797.44
  • 1M
  • 1Y
Interactive CRE2489 Chart

Previous Close

Fund Profile & Information for CRE2489

Dexia Equities B Pharma Plus is an open-end fund registered in Belgium. The objective is long-term growth and risk management through diversification. The Fund invest predominantly in US and European stocks of the pharmaceutical, healthcare, and biotechnology sectors. The Fund may also invests in options, warrants and futures. The benchmark is the MSCI World Health Care Index in USD.

Inception Date: 06-04-1997 Telephone: +32-2-222-11-11
Managers: RUDI VAN DEN EYNDE
Web Site: www.dexia-am.com

Fundamentals for CRE2489

NAV (on 2013-05-16) 1,797.44
Assets (M) (on 2013-05-16) 171.03
Fund Leveraged N
Minimum Investment -
Minimum Subsequent Investment -

Dividends for CRE2489

Dividend Type Income
Dividend Frequency Annual
Last Dividend Net (on 2012-10-09) 30.00
Dividend Yield (ttm) 1.67

Fees & Expenses for CRE2489

Front Load 2.50
Back Load 0.00
Current Mgmt Fee 1.50
Redemption Fee 0.00
12b1 Fee -
Expense Ratio 1.80

Top Fund Holdings for CRE2489

Filing Date: 03/28/2013
Name Position Value % of Total
Roche Holding AG 44,000 10,268,758 7.024%
Johnson & Johnson 123,000 10,028,190 6.860%
Pfizer Inc 340,000 9,812,400 6.712%
Novartis AG 117,000 8,333,756 5.701%
Merck & Co Inc 146,000 6,457,580 4.417%
Sanofi 59,000 6,005,646 4.108%
Bayer AG 44,000 4,546,587 3.110%
GlaxoSmithKline PLC 160,000 3,737,817 2.557%
Amgen Inc 36,000 3,690,360 2.524%
Gilead Sciences Inc 72,000 3,522,960 2.410%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Financial Commentaries

Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil